Hinge Bio Raises $30 Million Series A’ Financing to Develop Next-Generation Therapies via its Proprietary GEM-DIMER Platform
January 15, 2025 07:00 ET
|
Hinge Bio, Inc.
BURLINGAME, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Hinge Bio, Inc., a privately-held biotechnology company, today announced the close of a Series A’ financing led by Point72. Joining Point72 are...
Hinge Bio Presents Preclinical Data from its GEM-DIMER™ Programs Targeting B Cell Depletion at the American College of Rheumatology (ACR) Convergence 2024
November 14, 2024 07:00 ET
|
Hinge Bio, Inc.
BURLINGAME, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Hinge Bio, Inc., a privately-held biotechnology company, today announced that Daniel Capon, Ph.D., Chief Scientific Officer, and Juha Punnonen,...
Hinge Bio, Inc. Chief Scientific Officer, Daniel Capon, Ph.D., to Present its GEM-DIMER™ Platform Technology at the University of Oxford, Kennedy Institute of Rheumatology’s Annual Translational Research Conference
August 14, 2024 08:00 ET
|
Hinge Bio, Inc.
BURLINGAME, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Hinge Bio, Inc., a privately held biotechnology company in the San Francisco Bay Area, today announced that Daniel Capon, Ph.D., Founder &...
Hinge Bio Expands Senior Management Team to Drive GEM-DIMER™ Programs to Clinical Development
January 18, 2023 08:00 ET
|
Hinge Bio, Inc.
Barry Selick, Ph.D., successful biopharmaceutical scientist, senior executive and entrepreneur, appointed Chief Executive Officer Carin Rollins, Hinge Bio co-founder, becomes Chief Operating...